Latest Sirolimus Stories
Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease –– although it will be a few years before it becomes available for clinical testing.
Rapamycin, an immunosuppressant typically used to prevent rejection in organ transplants, could help prevent diminishing cognitive skills, including memory retention, associated with aging or Alzheimer's disease.
Johns Hopkins scientists have engineered cells that behave like AND and OR Boolean logic gates, producing an output based on one or more unique inputs.
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients.
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumor cells.
Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging.
- totally perplexed and mixed up.